Episode 28: Intuitive Surgical, The Quiet Robotics Compounder
A note before listening: We recorded this conversation on May 15, 2026, when Intuitive Surgical was trading at roughly $420 per share. As of July 21, the stock is trading around $354—approximately 16% lower. If we found the business compelling at $420, it is certainly worth another look at today’s price.
Intuitive Surgical is one of the great zero-to-one business stories of the past 30 years.
The company helped create robotic surgery, built a dominant ecosystem around its da Vinci platform, and quietly became one of the world’s most successful medical-technology companies. Today, it has thousands of systems installed around the world, millions of annual procedures, and a recurring-revenue engine built around instruments, accessories, and service.
But is the next chapter already priced into the stock?
In this episode, we trace Intuitive Surgical’s evolution from a Stanford research project into the leader in robotic surgery. We explore the company’s competitive advantages—including surgeon training, clinical evidence, hospital workflows, regulatory approvals, and decades of procedural data—and ask whether those advantages can withstand growing competition.
We also discuss the potential beyond Intuitive’s traditional surgical markets. Could its Ion platform, expansion into cardiac procedures, international growth, and AI-powered surgical assistance turn Intuitive into something much larger than a medical-device company?
The central question: Is Intuitive Surgical simply an expensive, high-quality compounder—or an underappreciated robotics and AI platform approaching another inflection point?
